Business
Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
- A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study -
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"- A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study -\n NEWTON, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that its late-breaking abstract detailing results from the pivotal, Phase 3 BOSTON study has been selected for oral presentation at the upcoming American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program taking place May 29-31, 2020. The BOSTON study is evaluating once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy. In addition to the BOSTON abstract, four additional abstracts were selected for presentation during the virtual program, including two poster presentations highlighting updated results from Darzalex® (daratumumab) and Kyprolis® (carfilzomib) arms of the ongoing Phase 1b/2 STOMP study evaluating XPOVIO in combination with backbone therapies in patients with relapsed or refractory multiple myeloma. The two remaining selected abstracts include a trial-in-progress (TIP) poster describing the ongoing Phase 3 SIENDO study evaluating XPOVIO as a maintenance therapy in patients with advanced or recurrent endometrial cancer following one prior platinum-based treatment, and a poster describing molecular predictors of selinexor response in recurrent glioblastoma. “We are honored that the full results from the pivotal Phase 3 BOSTON study have been selected for oral presentation at ASCO 2020, and we are excited to further engage with the medical community regarding these important data,” said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. “We are actively preparing the BOSTON results for submission to the U.S. Food and Drug Administration as part of a supplemental New Drug Application seeking to expand the approved indication for XPOVIO into second line treatment for patients with relapsed or refractory multiple myeloma. If approved, the SVd regimen tested in the BOSTON study would be the first and only FDA-approved combination drug regimen that...